RT Journal Article SR Electronic T1 Kit Gene in Endometrial Carcinoma: An Immunohistochemical and Mutational Analysis JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP 203 OP 205 DO 10.1097/IGC.0b013e3182055c94 VO 21 IS 2 A1 Ingrid Vandenput A1 Maria Debiec-Rychter A1 An Capoen A1 Godelieve Verbist A1 Ignace Vergote A1 Philippe Moerman A1 Frédéric Amant YR 2011 UL http://ijgc.bmj.com/content/21/2/203.abstract AB Objective: Because the outcome of recurrent disease of endometrial carcinoma is cumbersome, the development of target treatment strategies is critical. We evaluated KIT, a receptor tyrosine kinase, to determine a potential role for imatinib mesylate in the treatment of endometrial carcinoma.Materials and Methods: Immunohistochemical analysis for KIT expression was performed on paraffin sections from 45 patients: 30 primary and 15 recurrent tumors. Fifteen primary cases were available for mutation analysis.Results: Histopathological distribution of paraffin-embedded tissue was as follows: 30 type I and 15 type II endometrial carcinoma. Histopathological distribution of fresh-frozen tissue was as follows: 8 type I and 7 type II. Cases did not show KIT expression or mutations in mutational hotspot exons of KIT gene.Conclusions: On the basis of the absence of KIT expression or mutations, endometrial carcinoma is unlikely to respond to imatinib mesylate.